{
    "2021-12-23": [
        [
            {
                "time": "2021-12-23",
                "original_text": "恒瑞医药现1笔大宗交易 ，共成交420.14万元",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "大宗交易",
                        "成交"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12-23",
                "original_text": "恒瑞医药今日大宗交易成交8.50万股，成交价49.41元溢价0.0%",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "大宗交易",
                        "成交价",
                        "溢价"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12-23",
                "original_text": "人民金融·创新药指数涨0.94% | 2021年上市国产1类再创纪录，这些重磅品种有望明年获批",
                "features": {
                    "keywords": [
                        "创新药指数",
                        "上涨",
                        "国产1类",
                        "重磅品种"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12-23",
                "original_text": "恒瑞医药（600276.SH）：HRS5685片获批开展用于治疗HIV-1感染者的临床试验",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "HRS5685片",
                        "临床试验",
                        "HIV-1"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12-23",
                "original_text": "恒瑞医药：公司目前生产经营情况正常",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "生产经营",
                        "正常"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12-23",
                "original_text": "恒瑞医药：公司部分仿制药需要开展临床试验",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "仿制药",
                        "临床试验"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12-23",
                "original_text": "恒瑞医药：公司创新药脯氨酸恒格列净、磷酸瑞格列汀等目前均已处于申报上市状态",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "创新药",
                        "申报上市"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12-22",
                "original_text": "A股融资融券日报：两融余额增加24.04亿元",
                "features": {
                    "keywords": [
                        "A股",
                        "融资融券",
                        "两融余额",
                        "增加"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "市场整体"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12-23",
                "original_text": "十年融资七百亿、“烧钱”搞研发 百济神州到底是不是“虚胖”？",
                "features": {
                    "keywords": [
                        "百济神州",
                        "融资",
                        "研发",
                        "烧钱",
                        "虚胖"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}